Despite the marked improvement in the overall survival (OS) for patients diagnosed with Wilms' tumor (WT), the outcomes for those who experience relapse have remained disappointing. We describe the outcomes of 253 patients with relapsed WT who received high-dose chemotherapy (HDT) followed by autologous hematopoietic stem cell transplant (HCT) between 1990 and 2013, and were reported to the Center for International Blood and Marrow Transplantation Research. The 5-year estimates for event-free survival (EFS) and OS were 36% (95% confidence interval (CI); 29-43%) and 45% (95 CI; 38-51%), respectively. Relapse of primary disease was the cause of death in 81% of the population. EFS, OS, relapse and transplant-related mortality showed no significant differences when broken down by disease status at transplant, time from diagnosis to transplant, year of transplant or conditioning regimen. Our data suggest that HDT followed by autologous HCT for relapsed WT is well tolerated and outcomes are similar to those reported in the literature. As attempts to conduct a randomized trial comparing maintenance chemotherapy with consolidation versus HDT followed by stem cell transplant have failed, one should balance the potential benefits with the yet unknown long-term risks. As disease recurrence continues to be the most common cause of death, future research should focus on the development of consolidation therapies for those patients achieving complete response to therapy.
INTRODUCTION
Each year~500 children in the United States are diagnosed with Wilms tumor (WT). 1 The outcomes for children with WT have improved dramatically with the advent of multi-modal therapy, and survival rates are currently approaching 90%. 2 With improved chemotherapy the overall relapse rate for children with WT has decreased to o 15%. [3] [4] [5] However, long-term survival for patients who relapse and are re-treated with chemotherapy and surgery alone have been disappointing, with~50% of patients dying of disease by 4 years. [6] [7] [8] [9] The identification of prognostic factors associated with risk of treatment failure after relapse has allowed for risk-adapted treatment strategies. In the most recent National Wilms' Tumor Study-5 children who relapsed after minimal initial therapy with VCR and actinomycin have a 480% 4-year overall survival (OS) rate. 10 However, the 4-year OS rate was o 50% for those who relapsed after receiving these two drugs plus doxorubicin and radiation. 11 Owing to the poor long-term outcomes of patients with relapsed WT, many investigators have used high-dose therapy (HDT) followed by autologous hematopoietic stem cell transplant (HCT) in a non-randomized fashion and reports usually consist of small institutional series or review articles. Since the first EBMT (European Bone Marrow Transplant) report, the number of relapsed WT patients transplanted in the EBMT registry has continued to grow. 12 When compared with historical controls of patients treated with conventional chemotherapy, these trials obtained better outcomes, with 3-or 4-year OS rates ranging from 60 to 73%. [13] [14] [15] [16] [17] Taken together, these studies suggest a potential survival advantage of HDT with autologous HCT over conventional chemotherapy in patients with relapsed WT and a good response to re-induction therapy, although increased toxicity is a major Survival in Wilms' tumor after autologous transplant concern. However, this small advantage may be a result of the small number of patients enrolled in each study and a possible selection bias.
To investigate the role of HDT followed by autologous HCT in pediatric patients with relapsed WT, we sought to utilize the Center for International Blood and Marrow Transplant Research (CIBMTR) database to describe outcomes of patients transplanted from 1990 to 2013 and reported to CIBMTR.
PATIENTS AND METHODS Patients
Data were obtained from the CIBMTR, a working group of more than 500 transplant centers worldwide that provide patient, disease and transplant characteristics including outcomes for consecutive transplantations to a statistical center coordinated through the NMDP (National Marrow Donor Program). All HCTs have basic information collected; selected transplants have more detailed information collected. For this, only information from the basic level forms was available. Patients or guardians provided written informed consent for data submission and research participation in accordance with the Declaration of Helsinki. The Institutional Review Boards of the Medical College of Wisconsin and NMDP approved this study.
Eligibility criteria
Patients with recurrent WT treated with autologous HCT between 1990 and 2013 who were younger than 21 years at the date of initial diagnosis were eligible for inclusion. Patients were excluded if they were untreated prior to transplant, or were treated at a center with low follow-up (the percentage of patients who were not dead nor lost to follow-up was o20% at 5-years post transplant).
Endpoints
The primary objective of this study was to describe event-free survival (EFS) with the secondary outcomes being OS, post-HCT relapse and transplant-related mortality (TRM). EFS was defined as survival without relapse or disease progression. Relapse was defined as the recurrence of WT. TRM was defined as death in the first 28 days post transplant or death in continuous remission. OS was defined as survival from all causes.
Statistical analysis
The probabilities of EFS and OS were calculated using the Kaplan-Meier estimator. [18] [19] [20] Ninety-five percent confidence intervals were calculated using log transformation. EFS was defined as the time interval between HCT and relapse, disease progression or death whichever occurs first. Patients surviving in remission were censored at the date of last follow-up. OS was defined as the time interval between HCT and death from any cause. Patients surviving were censored at the date of last follow-up. The cumulative incidences of relapse and TRM were estimated using the cumulative incidence function with TRM as the competing risk for relapse and relapse as the competing risk for TRM.
In multivariate analysis, the Cox proportional hazards model was used to identify significant risk factors. Variables tested in the Cox proportional hazards regression model included disease status at transplantation (first pre-transplant relapse versus second or greater pre-transplant relapse or continuous remission versus persistent/progressive disease versus missing), time from diagnosis to transplantation (o 12 months versus 12-18 months versus 418 months), graft type (bone marrow (BM) versus PBSC), year of transplant (1990-1994 versus 1995-1999 versus 2000-2004 versus 2005-2013) and conditioning regimen (alkylating agents (cyclopho-sphamide+melphalan, busulfan+cyclophosphamide, busulfan+melphalan, melphalan, cyclophosphamide+thiotepa, cyclophosphamide) versus platinum agents (carboplatin+melphalan, cyclophosphamide+carboplatin, carboplatin)). The assumption of proportional hazards for each factor was tested using time-dependent covariates. When the test indicated differential effects over time (non-proportional hazards), models were constructed breaking the post-transplant time course into two periods, using the maximized partial likelihood method to find the most appropriate breakpoint. The proportionality assumptions were further tested. A stepwise model selection approach was used to identify all significant risk factors. Factors that were significant at a 5% level were kept 
RESULTS
Patient, disease and transplant characteristics of 253 children with WT by transplant period and disease status at transplantation are shown in Tables 1 and 2 . The median patient age at HCT was 6 years (range 1-23), with 135 (53%) patients being female. According to the available data, 62% (152/253) of the patients were transplanted while in remission and 25% (62/253) of the patients were transplanted with disease present. Among patients transplanted in remission, 67% (106/158) of the patients were in CR2 or more and 20% were in PR at time of transplant. The median time from diagnosis to transplant was 18 months (range 5-208). Fifty-one percent of the patients were transplanted 18 months or longer after their diagnosis, 73 (29%) were transplanted 12-18 months after diagnosis and 51 (20%) were transplanted o12 months after diagnosis. The most common source of autologous stem cells for patients enrolled on this study was PBSC (n = 195, 77%). The number of patients transplanted in each study period was: 33 (13%) between 1990 and 1994, 67 (26%) between 1995 and 1999, 52 (21%) between 2000 and 2004 and 101 (40%) between 2005 and 2013. HCT conditioning included alkylating agents in 142 (56%) of the patients, 75 patients (30%) received platinum agents and 36 (14%) were missing conditioning information. The median follow-up of survivors is 57 months (range 1-241). Fourteen (6%) patients received a second transplant. Nine (64%) of second HCT happened within 2 months of the first transplant and were likely scheduled tandem HCTs, all happening after 2000.
The median follow-up of survivors was more than 92 months (range 1-241) for patients treated between 1990 and 2004, and 26 months (range 3-94) for those treated between 2005 and 2013.
Outcomes
The 5-year EFS and OS rates for all patients were 36% (95% CI; 29-43%) and 45% (95% CI; 38-51%). Figures 1a and b 
show the probabilities of EFS and OS by transplant period and Figures 2a and b show the probabilities of EFS and OS by disease status at transplantation.
Relapse of primary disease was the cause of death in 81% of the patients (104 out of 129 evaluable deaths). There were no significant differences in 1, 2, 3 and 5-year EFS OS, relapse and TRM estimates when outcomes were analyzed by univariate analysis according to disease status at transplant, time from diagnosis to transplant, graft source, conditioning regimen and year of transplant (Table 3) . Overall the 1 year TRM incidence was low (4-9%) and did not vary significantly over the length of the study. An analysis of patients who received autologous HCT when not in remission compared with those who were in remission did not show significant differences.
Conditioning regimen was the only factor found to be statistically significant by multivariate analysis ( Table 4 ). The effect of conditioning regimen on overall mortality changed over time. The use of platinum agents was associated with lower mortality in the first 10 months after HCT but not thereafter. This timedependent effect explains why in univariate analysis there were no differences in survival by conditioning regimen.
DISCUSSION
Relapsed WT is rare, but outcomes for these patients remain suboptimal. HDT followed by autologous HCT has been used to salvage patients with WT who relapse after chemotherapy. This retrospective study using the CIBMTR database includes one of the largest numbers of patients with recurrent WT treated with HDT followed by autologous HCT reported to date.
The number of HCT per year has not changed significantly since 1995. However, over time, there was a clear trend in change of practice from BM as a stem cell source to PBSC. During the first analysis period, 1990-1994, BM was the most common source of stem cells (70%) and it was almost completely replaced by PBSC (93%) in the most recent period, 2005 to 2013.
The conditioning regimens were varied and included alkylating agents for 142 (56%) patients. Platinum-containing regimens became more common during the most recent period (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) . The large number of different conditioning regimens used in the treatment of these patients, highlights one of the biggest challenges for the development of a common approach for these patients. Although our data identified that the use of platinum agents was associated with lower mortality in the first 10 months post transplant, this effect was no longer seen after that. EFS and OS between patients treated with HDT followed by HCT with dose treated without HDT (conventional chemotherapy). 21 The median 3-year EFS and OS for patients who did not received HDT was 47.6% (1.76-79.83%) and 47.5% (3.7-100%), respectively, compared with 47% (3.7-100%) and 47.5% (12.5-100%) for those treated with HDT followed by HCT. 21 The authors concluded that the evidence suggests the value of HDT followed by HCT, particularly for those in the highest risk relapse group based on initial stage, histology, initial treatment received and prior relapse. A recent international meta-analysis conducted by Presson et al. 22 to provide additional insights into the role of HDT followed by HCT revealed that the patients most likely to benefit from this approach were those initially treated with four or more chemotherapeutic agents and those with multiple relapses or progression on salvage therapy.
The biggest limitation of our study is the fact that this study is a retrospective registry-based analysis and that the available data originate from basic level forms, and therefore, did not include the following diagnosis variables: histology, site of metastases, stage of disease, genetic syndrome, tumor spillage and radiation. The following pre-transplant variables were also not available for the majority of the patients: site, time from diagnosis to relapse. Different from the two studies mentioned above, this lack of detailed data did not allow us to investigate if there is a risk-group of patients who could benefit from the use HDT followed by autologous HCT. Consequently, our observation of an absence in EFS and OS by disease status must be interpreted with caution as several pertinent disease and treatment characteristics including histopathological features at diagnosis were not studied.
Unlike other previous reports, 3,5,7,10-16 our results were not influenced by time from diagnosis to transplant, graft source or conditioning regimen. The survival outcomes found in this study are not different from those obtained in previous reports using systemic chemotherapy alone or HDT followed by HCT. [21] [22] Overall, the use of HDT followed by autologous HCT appears to be useful for the full spectrum of disease states. However, the retrospective nature, heterogeneous nature of relapsed Wilms' tumor relatively small patient numbers limit this study. The lack of a complete supplemental data set limits the strength of the conclusions and is a reminder of the importance of data collection and submission, particularly in rare diseases.
Our data, including considering its limitations together with those from previous studies suggest that HDT followed by autologous HCT for relapsed WT is well tolerated. The EFS and OS for our study was not different than those reported by Ha et al. 21 and Presson et al. 22 for patients with relapsed WT treated with HCT or standard chemotherapy. As attempts to conduct a randomized trial comparing maintenance chemotherapy with consolidation with HDT followed by stem cell transplant have failed, one should balance the potential benefits of such an approach with the yet unknown long-term risks associated with this approach when deciding which patient should be submitted HDT followed by autologous HCT. As disease recurrence continues to be the most common cause of death for patients who received standard chemotherapy or HDT followed by autologous HCT, future research should focus on the development of consolidation therapies for those patients achieving complete response to therapy.
